GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Ampio Pharmaceuticals AMPE · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.18

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Ampio Pharmaceuticals — daily AMPE Delayed
Market value
$148,329
Last close × shares
Volume
334
Shares, 30 Oct 2026

About Ampio Pharmaceuticals

Its shares trade under the ticker AMPE. It has been listed since 19 May 2011. In the fiscal year to 31 December 2015, it reported revenue of $1.2m and a net loss of $32.0m. At that date it held total assets of $50.4m and shareholders' equity of $37.0m.

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development of therapies to treat prevalent inflammatory conditions. The company is headquartered in Englewood, Colorado. The company went IPO on 2011-05-19. The firm is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The firm's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The firm is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

Figures and description from our data supplier, not checked against the company's own report.

More about Ampio Pharmaceuticals →

How it makes its money

Revenue, year to 31 Dec 2015

  • Aytu Segment [Member] $1.2m · 100.0%

Latest on Ampio Pharmaceuticals

Our reporting

We have not reported on Ampio Pharmaceuticals yet.

Next results

12 Nov 2026

Due on 12 Nov 2026. Analysts expect earnings of -6.00 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Ampio Pharmaceuticals's ticker?

Ampio Pharmaceuticals trades as AMPE on its US listing, under ISIN US03209T3077.

What was Ampio Pharmaceuticals's last closing price?

0.18 on 30 Oct 2026. The figure is in USD and is never converted.

When does Ampio Pharmaceuticals next report results?

Results are expected on 12 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.